Výsledky vyhledávání - "Tammy Bratton Coberly"

Impact of Addition of Carboplatin AUC ≥ 4 to Antiemetic Guidelines for Triple Antiemetic Prophylaxis: A Gap in Quality of Care, Guideline Adoption, and Avoiding Acute Care

Autor: Kathryn J. Ruddy, Ravi Potluri, Rebecca Clark-Snow, Rita J Wickham, Thomas W. LeBlanc, Gary Binder, Rudolph M. Navari, Luke M. Schmerold, Tammy Bratton Coberly, Eric Roeland

Publikováno v: JCO oncology practice. 16(2)

PURPOSE: After ASCO and National Comprehensive Cancer Network guideline recommendations for triple antiemetic prophylaxis for carboplatin area under the curve (AUC) ≥ 4, and the publication of studies documenting avoidable acute care after chemothe

Externí odkaz: https://explore.openaire.eu/search/publication?articleId=doi_dedup___::f84d11d0c535f67ef2888a3ee438d78e
https://pubmed.ncbi.nlm.nih.gov/31800352

Zobrazit plný text záznamu

Physician concordance with update to ASCO guidelines for antiemetic use with carboplatin AUC ≥ 4

Autor: Tammy Bratton Coberly, Rebecca Clark-Snow, Ravi Potluri, Rita Wickham, Thomas W. LeBlanc, Rudolph M. Navari, Luke M. Schmerold, Eric Roeland, Kathryn J. Ruddy, Gary Binder

Publikováno v: Journal of Clinical Oncology. 37:11595-11595

11595 Background: In 2017, NCCN (2/2017) and ASCO (8/2017) each amended antiemetic guidelines to classify carboplatin AUC ≥4 as highly emetogenic chemotherapy (HEC), recommending upfront triple prophylaxis with an NK1 receptor antagonist (RA) + 5HT

Externí odkaz: https://explore.openaire.eu/search/publication?articleId=doi_________::7363031ba6b41f72bab8606a24decd22
https://doi.org/10.1200/jco.2019.37.15_suppl.11595

Zobrazit plný text záznamu

Vyhledávací nástroje:

Upřesnit hledání